Search | GSK

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

Media

First published: 29 September 2021

The Phase 3 TANGO study is the 3rd trial to provide long-term evidence for Dovato reinforcing its use as a viable switch for people with HIV

https://www.gsk.com/en-gb/media/press-releases/viiv-presents-three-year-switch-data-for-dovato-confirming-long-term-non-inferior-efficacy-with-no-virologic-failure-versus-continuation-of-taf-based-regimens-of-at-least-three-drugs/

ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

Media

First published: 01 February 2022

Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Media

First published: 07 February 2022

ViiV Healthcare to present new long-term findings at CROI 2022

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-long-term-findings-from-its-innovative-2-drug-and-long-acting-hiv-medicines-portfolio-at-croi-2022/

IAS 2019: ViiV Healthcare showcasing innovation in HIV science

Media

First published: 15 July 2019

Data to be presented span the company’s diverse portfolio, challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living with HIV

https://www.gsk.com/en-gb/media/press-releases/ias-2019-viiv-healthcare-showcasing-innovation-in-hiv-science/

ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

Media

First published: 19 December 2016

First phase III studies to show efficacy of two-drug regimen as maintenance therapy

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Media

First published: 16 October 2020

Long-acting regimen is based on co-administration of cabotegravir and rilpivirine injections once-monthly or once every 2-months

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-positive-chmp-opinion-for-long-acting-regimen-for-the-treatment-of-hiv/

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Media

First published: 21 December 2020

New treatment can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-the-marketing-authorisation-of-the-first-complete-long-acting-injectable-hiv-treatment-in-europe/

ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress

Media

First published: 30 September 2020

Data presented will reinforce the potential to shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-long-term-safety-and-efficacy-data-for-2-drug-regimen-dovato-dolutegravirlamivudine-alongside-other-key-research-advances-at-the-hiv-glasgow-2020-congress/